Synova Life Sciences

Executive Summary

Synova Life Sciences is a private biotechnology company headquartered in New York, USA, pioneering a novel cell therapy platform leveraging its proprietary Synova WAVE process to isolate and process adipose-derived cells. The company's technology demonstrates high viability (median 91.2%) and metabolic activity, positioning it for applications in oncology and regenerative medicine. Founded in 2019, Synova is in the preclinical stage and has not disclosed total funding, valuation, or specific pipeline candidates. However, its focus on adipocyte-based therapies for cancer represents a differentiated approach in the cell therapy landscape. The company's progress is limited by early-stage risk and lack of public data, but its technological foundation shows promise for addressing unmet medical needs in solid tumors.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data Release50% success
• Q4 2026GMP Manufacturing Scale-Up Completion60% success
• TBDStrategic Partnership or Licensing Agreement30% success